Aspire Biopharma Holdings, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ASBP Nasdaq 2834 aspirebiolabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aspire Biopharma Holdings, Inc.

BC-Most Active Stocks - Jan 14th, 2026 8:30 am
Aspire Biopharma Announces Reverse Stock Split - Jan 14th, 2026 6:00 am
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Jan 7th, 2026 6:00 am
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - Dec 18th, 2025 6:30 am
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Dec 12th, 2025 3:00 pm
Aspire Biopharma Provides Q3 2025 Business Update - Dec 4th, 2025 7:00 am
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Dec 2nd, 2025 7:00 am
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Nov 26th, 2025 7:00 am
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Nov 6th, 2025 7:00 am
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform - Oct 6th, 2025 6:30 am
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025 - Oct 3rd, 2025 9:30 am
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication - Oct 1st, 2025 6:30 am
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product - Sep 17th, 2025 6:30 am
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement - Sep 16th, 2025 6:30 am
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Sep 3rd, 2025 6:30 am
Sidoti Events, LLC's Virtual August Micro-Cap Conference - Aug 19th, 2025 6:00 am
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Aug 18th, 2025 6:30 am
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Aug 14th, 2025 6:00 am
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Aug 13th, 2025 7:10 am
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Jul 31st, 2025 6:30 am